A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background: Activating mutations or structural rearrangements in BRAF are identified in roughly 75% of all pediatric low-grade astrocytomas (PLGAs). However, first-generation RAF inhibitors approved for adult melanoma have poor blood-brain penetrance and are only effective on tumors that express the canonical BRAFV600E oncoprotein, which functions as a monomer. These drugs (type I antagonists that target the "DFG-in" conformation of the kinase) fail to block signaling via KIAA1549:BRAF, a truncation/fusion BRAF oncoprotein which functions as a dimer and is found in the most common form of PLGA. Methods: A panel of small molecule RAF inhibitors (including type II inhibitors, targeting the "DFG-out" conformation of the kinase) was screened for drugs showing efficacy on murine models of PLGA and on authentic human PLGA cells expressing KIAA1549:BRAF. Results: We identify a type II RAF inhibitor that serves as an equipotent antagonist of BRAFV600E, KIAA1549:BRAF, and other noncanonical BRAF oncoproteins that function as dimers. This drug (MLN2480, also known as TAK-580) has good brain penetrance and is active on authentic human PLGA cells in brain organotypic cultures. Conclusion: MLN2480 may be an effective therapeutic for BRAF mutant pediatric astrocytomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting RAS–ERK signalling in cancer: promises and challenges
Samatar, A. A., & Poulikakos, P. I. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4281 · Cited by 1,163
Tumor adaptation and resistance to RAF inhibitors
Lito, P., Rosen, N., & Solit, D. B. (2013) · Nature Medicine · doi:10.1038/nm.3392 · Cited by 585
Self-citationLito, P., Pratilas, C. A., Joseph, E. W., Tadi, M., Halilovic, E., Zubrowski, M., Huang, A., Wong, W. L., Callahan, M. K., Merghoub, T., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.10.009 · Cited by 562
Self-citationYao, Z., Torres, N. M., Tao, A., Gao, Y., Luo, L., Li, Q., de Stanchina, E., Abdel-Wahab, O., Solit, D. B., Poulikakos, P. I., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.08.001 · Cited by 543
Self-citationGirotti, M. R., Lopes, F., Preece, N., Niculescu-Duvaz, D., Zambon, A., Davies, L., Whittaker, S., Saturno, G., Viros, A., Pedersen, M., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.006 · Cited by 212
Phosphorylation State of Olig2 Regulates Proliferation of Neural Progenitors
Sun, Y., Meijer, D. H., Alberta, J. A., Mehta, S., Kane, M. F., Tien, A.-C., Fu, H., Petryniak, M. A., Potter, G. B., Liu, Z., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.02.005 · Cited by 116
Self-citation
Cited by
RAS-targeted therapies: is the undruggable drugged?
Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies
Bahar, M. E., Kim, H. J., & Kim, D. R. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01705-z · Cited by 888
“398,399 However, the use of these inhibitors in patients has been limited by a lack of selectivity for mutant BRAF.”
BackgroundRAF-MEK-ERK pathway in cancer evolution and treatment
Ullah, R., Yin, Q., Snell, A. H., & Wan, L. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.010 · Cited by 553
Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations
Dankner, M., Rose, A. A. N., Rajkumar, S., Siegel, P. M., & Watson, I. R. (2018) · Oncogene · doi:10.1038/s41388-018-0171-x · Cited by 550
Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
Degirmenci, U., Wang, M., & Hu, J. (2020) · Cells · doi:10.3390/cells9010198 · Cited by 534
The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy
Yuan, J., Dong, X., Yap, J., & Hu, J. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00949-4 · Cited by 493
New perspectives for targeting RAF kinase in human cancer
Karoulia, Z., Gavathiotis, E., & Poulikakos, P. I. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.79 · Cited by 404
BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall
Leonetti, A., Facchinetti, F., Rossi, G., Minari, R., Conti, A., Friboulet, L., Tiseo, M., & Planchard, D. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.04.006 · Cited by 168
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma
Yen, I., Shanahan, F., Lee, J., Hong, Y. S., Shin, S. J., Moore, A. R., Sudhamsu, J., Chang, M. T., Bae, I., Dela Cruz, D., et al. (2021) · Nature · doi:10.1038/s41586-021-03515-1 · Cited by 138
BRAF — a tumour-agnostic drug target with lineage-specific dependencies
Hanrahan, A. J., Chen, Z., Rosen, N., & Solit, D. B. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00852-0 · Cited by 136
“Tovorafenib has also been shown to be brain-penetrant and active in models of paediatric low-grade astrocytoma harbouring BRAF fusions 132 .”
Self-citationPal, S., Kozono, D., Yang, X., Fendler, W., Fitts, W., Ni, J., Alberta, J. A., Zhao, J., Liu, K. X., Bian, J., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3691 · Cited by 101
Self-citationBuhl, J. L., Selt, F., Hielscher, T., Guiho, R., Ecker, J., Sahm, F., Ridinger, J., Riehl, D., Usta, D., Ismer, B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1965 · Cited by 84
“Another murine glioma model of pilocytic astrocytoma was established by transduction of either BRAF or the KIAA1549:BRAF fusion in TP53-null murine neural progenitor cells (13).”
Background
Metadata
- Authors
- Sun, Y., Alberta, J. A., Pilarz, C., Calligaris, D., Chadwick, E. J., Ramkissoon, S. H., Ramkissoon, L. A., Garcia, V. M., Mazzola, E., Goumnerova, L., Kane, M., Yao, Z., Kieran, M. W., Ligon, K. L., Hahn, W. C., Garraway, L. A., Rosen, N., Gray, N. S., Agar, N. Y., Buhrlage, S. J., Segal, R. A., & Stiles, C. D.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-01-12
- Volume
- 19
- Issue
- 6
- Pages
- now261
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W2576797066
- Cited by
- 105
- References
- 6
- FWCI
- 5.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.